To that end, the purpose of this study was to evaluate the existing literature regarding serum IGF-1 levels in de novo, drug-naïve PD patients in comparison with healthy controls, and synthesize a thorough meta-analysis which may facilitate future investigations into novel ways to diagnose, estimate prognosis and initiate early therapy in patients with PD. The gene discussed is IGF1; the disease is Parkinson disease.